Nyxoah SA

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nyxoah reports mixed Q1 results, eyes strategic growth in 2023

Nyxoah's Q1 performance showed mixed results but with positive developments in the DREAM study and commercial rebound in Q2. The company aims for strategic growth in 2023 through market expansion and study advancements.

Nyxoah reports Q2 revenue growth, eyes FDA approval for U.S. market

Nyxoah's Q2 performance showed revenue growth and ongoing investments in market expansion. The company's strengths lie in Genio's features and upcoming milestones. Addressing challenges and seizing opportunities will be key for Nyxoah's future success.

Nyxoah reports Q3 revenue growth, eyes FDA approval by 2024

Nyxoah's Q3 performance reflects progress in key strategic areas, with a focus on patient-centric approaches and market expansion.
While facing challenges in managing expenses and regulatory timelines, the company is well-positioned for future growth and FDA approval by late 2024.
Opportunities lie in market expansion, partnerships, and innovative approaches to drive revenue growth and market penetration across regions.
Overall, Nyxoah's earnings call highlights a mix of strengths, challenges, and opportunities that shape its path towards leadership in the sleep disorder market.

Nyxoah SA reports robust Q4 sales and strategic 2024 plans

Nyxoah SA's Q4 2023 performance showcased strong sales growth and strategic accomplishments, setting the stage for future expansion.
While facing challenges in operating loss and cash burn, the company's financial position and upcoming milestones offer opportunities for growth.
Strategic partnerships and market positioning highlight Nyxoah's strengths in innovation and market differentiation.
Addressing market challenges and leveraging opportunities can drive Nyxoah's path towards profitability and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah to Release Full Year 2021 Financial Results on March 24 and Host Conference Call on March 25, 2022

Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Mont-Saint-Guibert, Belgium – January 10, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update.

Nyxoah Provides General Corporate Update

Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Mont-Saint-Guibert, Belgium – November 8, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Loïc Moreau will join Nyxoah as CFO as of January 1, 2022.

Nyxoah appoints new CFO

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients

The FDA has granted Breakthrough Device Designation to Nyxoah SA (NASDAQ: NYXH) Genio bilateral hypoglossal nerve stimulation system. The system treats adult patients with moderate to severe Obstructive Sleep Apnea (OSA) and Complete Concentric Collapse (CCC) of the soft palate.

Nyxoah's Sleep Apnea Device Receives FDA Breakthrough Tag

Nyxoah Announc es Participation in the Cantor 2021 Virtual Global Healthcare Conference

Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference

Nyxoah Announces Participation in the Baird 2021 Global Healthcare Conference

Nyxoah Issues First Half 2021 Financial Results

Nyxoah Appoints Rita Johnson-Mills to its Board of Directors

Mont-Saint-Guibert, Belgium. - August 11, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it will release financial results for the first half of 2021 on Tuesday, August 31, 2021, after the US markets close. Company management will host a conference call to discuss financial results on Wednesday, September 1, 2021, beginning at 3:00 p.m. CET / 9:00 a.m. ET.

Nyxoah to Release First Half 2021 Financial Results on August 31 and Host Earnings Conference Call on September 1, 2021

Publication relating to a transparency notification

Nyxoah Announces Closing of Nasdaq Initial Public Offering and Underwriters' Full Exercise of Option to Purchase Additional Shares

Mont-Saint-Guibert, Belgium – July 2, 2021, 2:40pm CET / 8:40am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the pricing of its initial public offering in the United States (the "Offering") of 2,835,000 ordinary shares at a price to the public of US$ 30 per share for total gross proceeds of US$ 85.1 million before deducting underwriting discounts and commissions and estimated offering expenses.

Nyxoah Announces Pricing of Nasdaq Public Offering

Nyxoah SA has filed proposed terms for its U.S. IPO. The firm is commercializing a novel device for treating obstructive sleep apnea.

Nyxoah SA Seeks $87 Million U.S. IPO

News for Nyxoah SA Stock (NYXH)